{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:09:53Z","timestamp":1773389393385,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T00:00:00Z","timestamp":1654560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s10067-022-06230-y","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T18:02:56Z","timestamp":1654624976000},"page":"2863-2874","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Identifying inadequate response among patients with ankylosing spondylitis and psoriatic arthritis prescribed advanced therapy in a real-world, commercially insured adult population in the USA"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8412-9175","authenticated-orcid":false,"given":"Theresa","family":"Hunter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Grabner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Birt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Isenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyang","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chia-Chen","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianmin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirstin","family":"Griffing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Lisse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey R.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,7]]},"reference":[{"key":"6230_CR1","doi-asserted-by":"publisher","first-page":"15013","DOI":"10.1038\/nrdp.2015.13","volume":"1","author":"J Sieper","year":"2015","unstructured":"Sieper J, Braun J, Dougados M et al (2015) Axial spondyloarthritis. Nat Rev Dis Primers 1:15013","journal-title":"Nat Rev Dis Primers"},{"key":"6230_CR2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S et al (2016) European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 75:499\u2013510","journal-title":"Ann Rheum Dis"},{"key":"6230_CR3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13075-019-1885-z","volume":"21","author":"DE Furst","year":"2019","unstructured":"Furst DE, Louie JS (2019) Targeting inflammatory pathways in axial spondyloarthritis. Arthritis Res Ther 21:135","journal-title":"Arthritis Res Ther"},{"key":"6230_CR4","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1136\/ard.2009.116764","volume":"69","author":"A Boonen","year":"2010","unstructured":"Boonen A, Brinkhuizen T, Landew\u00e9 R et al (2010) Impact of ankylosing spondylitis on sick leave, presenteeism and unpaid productivity, and estimation of the societal cost. Ann Rheum Dis 69:1123\u20131128","journal-title":"Ann Rheum Dis"},{"key":"6230_CR5","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1586\/14737167.2014.957679","volume":"14","author":"K Kotsis","year":"2014","unstructured":"Kotsis K, Voulgari PV, Drosos AA et al (2014) Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review. Expert Rev Pharmacoecon Outcomes Res 14:857\u2013872","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"6230_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s41927-019-0086-3","volume":"3","author":"J Walsh","year":"2019","unstructured":"Walsh J, Hunter T, Schroeder K et al (2019) Trends in diagnostic prevalence and treatment patterns of male and female ankylosing spondylitis patients in the United States, 2006\u20132016. BMC Rheumatol 3:39","journal-title":"BMC Rheumatol"},{"key":"6230_CR7","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/MAJ.0b013e31820f8c99","volume":"341","author":"JD Reveille","year":"2011","unstructured":"Reveille JD (2011) Epidemiology of spondyloarthritis in North America. Am J Med Sci 341:284\u2013286","journal-title":"Am J Med Sci"},{"key":"6230_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.7812\/TPP\/15-151","volume":"20","author":"JR Curtis","year":"2016","unstructured":"Curtis JR, Harrold LR, Asgari MM et al (2016) Diagnostic prevalence of ankylosing spondylitis using computerized health care data, 1996 to 2009: underrecognition in a US health care setting. Perm J 20:15\u2013151","journal-title":"Perm J"},{"key":"6230_CR9","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P (2015) The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am 41:545\u2013568","journal-title":"Rheum Dis Clin North Am"},{"key":"6230_CR10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jaad.2005.03.046","volume":"53","author":"JM Gelfand","year":"2005","unstructured":"Gelfand JM, Gladman DD, Mease PJ et al (2005) Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 53:573","journal-title":"J Am Acad Dermatol"},{"key":"6230_CR11","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/pds.3447","volume":"22","author":"MM Asgari","year":"2013","unstructured":"Asgari MM, Wu JJ, Gelfand JM et al (2013) Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996\u20132009. Pharmacoepidemiol Drug Saf 22:842\u2013849","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6230_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A et al (2019) Special Article: 2018 American College of Rheumatology\/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol 71:5\u201332","journal-title":"Arthritis Rheumatol"},{"key":"6230_CR13","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS et al (2019) 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol 71:1599\u20131613","journal-title":"Arthritis Rheumatol"},{"key":"6230_CR14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1002\/acr.22708","volume":"68","author":"MM Ward","year":"2016","unstructured":"Ward MM, Deodhar A, Akl EA et al (2016) American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res 68:151\u2013166","journal-title":"Arthritis Care Res"},{"key":"6230_CR15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/acr.23337","volume":"70","author":"MP Lee","year":"2018","unstructured":"Lee MP, Lii J, Jin Y et al (2018) Patterns of systemic treatment for psoriatic arthritis in the US: 2004\u20132015. Arthritis Care Res 70:791\u2013796","journal-title":"Arthritis Care Res"},{"key":"6230_CR16","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ et al (2016) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol 68:1060\u20131071","journal-title":"Arthritis Rheumatol"},{"key":"6230_CR17","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.clinthera.2013.07.328","volume":"35","author":"B Zhu","year":"2013","unstructured":"Zhu B, Edson-Heredia E, Gatz JL et al (2013) Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study. Clin Ther 35:1376\u20131385","journal-title":"Clin Ther"},{"key":"6230_CR18","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1002\/art.11325","volume":"48","author":"JC Davis Jr","year":"2003","unstructured":"Davis JC Jr, Van Der Heijde D, Braun J et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48:3230\u20133236","journal-title":"Arthritis Rheum"},{"key":"6230_CR19","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13075-017-1293-1","volume":"19","author":"M Grabner","year":"2017","unstructured":"Grabner M, Boytsov NN, Huang Q et al (2017) Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis. Arthritis Res Ther 19:92","journal-title":"Arthritis Res Ther"},{"key":"6230_CR20","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3389\/fphar.2017.00460","volume":"8","author":"P Li","year":"2017","unstructured":"Li P, Zheng Y, Chen X (2017) Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics. Front Pharmacol 8:460","journal-title":"Front Pharmacol"},{"key":"6230_CR21","doi-asserted-by":"publisher","first-page":"R155","DOI":"10.1186\/ar3471","volume":"13","author":"JR Curtis","year":"2011","unstructured":"Curtis JR, Baddley JW, Yang S et al (2011) Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. Arthritis Res Ther 13:R155\u2013R155","journal-title":"Arthritis Res Ther"},{"key":"6230_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40744-019-0148-4","volume":"6","author":"T Hunter","year":"2019","unstructured":"Hunter T, Schroeder K, Sandoval D et al (2019) Persistence, discontinuation, and switching patterns of newly initiated TNF inhibitor therapy in ankylosing spondylitis patients in the United States. Rheumatol Ther 6:207\u2013215","journal-title":"Rheumatol Ther"},{"key":"6230_CR23","doi-asserted-by":"publisher","first-page":"e000880","DOI":"10.1136\/rmdopen-2018-000880","volume":"5","author":"PJ Mease","year":"2019","unstructured":"Mease PJ, Karki C, Liu M et al (2019) Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry. RMD Open 5:e000880","journal-title":"RMD Open"},{"key":"6230_CR24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13075-019-1908-9","volume":"21","author":"U Lindstr\u00f6m","year":"2019","unstructured":"Lindstr\u00f6m U, Olofsson T, Wedr\u00e9n S et al (2019) Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice. Arthritis Res Ther 21:128","journal-title":"Arthritis Res Ther"},{"key":"6230_CR25","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/annrheumdis-2014-206616","volume":"74","author":"E Lie","year":"2015","unstructured":"Lie E, Kristensen LE, Forsblad-d\u2019Elia H et al (2015) The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study. Ann Rheum Dis 74:970\u2013978","journal-title":"Ann Rheum Dis"},{"key":"6230_CR26","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1080\/17512433.2020.1758556","volume":"13","author":"C Mekhail","year":"2020","unstructured":"Mekhail C, Chouk M, Prati C et al (2020) Prognostic factors of good response to DMARDs in psoriatic arthritis: a narrative review. Expert Rev Clin Pharmacol 13:505\u2013519","journal-title":"Expert Rev Clin Pharmacol"},{"key":"6230_CR27","first-page":"559","volume":"33","author":"R L\u00f3pez-Gonz\u00e1lez","year":"2015","unstructured":"L\u00f3pez-Gonz\u00e1lez R, Le\u00f3n L, Loza E et al (2015) Adherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: a systematic literature review. Clin Exp Rheumatol 33:559\u2013569","journal-title":"Clin Exp Rheumatol"},{"key":"6230_CR28","doi-asserted-by":"publisher","first-page":"e000017","DOI":"10.1136\/rmdopen-2014-000017","volume":"1","author":"JR Maneiro","year":"2015","unstructured":"Maneiro JR, Souto A, Salgado E et al (2015) Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open 1:e000017","journal-title":"RMD Open"},{"key":"6230_CR29","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.mayocp.2017.05.009","volume":"92","author":"CA Wijbrandts","year":"2017","unstructured":"Wijbrandts CA, Tak PP (2017) Prediction of response to targeted treatment in rheumatoid arthritis. Mayo Clin Proc 92:1129\u20131143","journal-title":"Mayo Clin Proc"},{"key":"6230_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13075-020-02337-2","volume":"22","author":"R Neuenschwander","year":"2020","unstructured":"Neuenschwander R, Hebeisen M, Micheroli R et al (2020) Differences between men and women with nonradiographic axial spondyloarthritis: clinical characteristics and treatment effectiveness in a real-life prospective cohort. Arthritis Res Ther 22:233","journal-title":"Arthritis Res Ther"},{"key":"6230_CR31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11926-018-0744-2","volume":"20","author":"T Rusman","year":"2018","unstructured":"Rusman T, van Vollenhoven RF, van der Horst-Bruinsma IE (2018) Gender differences in axial spondyloarthritis: women are not so lucky. Curr Rheumatol Rep 20:35\u201335","journal-title":"Curr Rheumatol Rep"},{"key":"6230_CR32","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/art.37876","volume":"65","author":"B Glintborg","year":"2013","unstructured":"Glintborg B, Ostergaard M, Krogh NS et al (2013) Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor \u03b1 inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum 65:1213\u20131223","journal-title":"Arthritis Rheum"},{"key":"6230_CR33","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1093\/rheumatology\/key140","volume":"57","author":"P H\u00f8jgaard","year":"2018","unstructured":"H\u00f8jgaard P, Ballegaard C, Cordtz R et al (2018) Gender differences in biologic treatment outcomes\u2014a study of 1750 patients with psoriatic arthritis using Danish Health Care Registers. Rheumatology 57:1651\u20131660","journal-title":"Rheumatology"},{"key":"6230_CR34","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J et al (2015) Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 373:2534\u20132548","journal-title":"N Engl J Med"},{"key":"6230_CR35","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH et al (2020) Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395:1115\u20131125","journal-title":"Lancet"},{"key":"6230_CR36","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB et al (2020) Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 395:1126\u20131136","journal-title":"Lancet"},{"key":"6230_CR37","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00296-018-4195-x","volume":"39","author":"A Gottlieb","year":"2019","unstructured":"Gottlieb A, Gratacos J, Dikranian A et al (2019) Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe. Rheumatol Int 39:121\u2013130","journal-title":"Rheumatol Int"},{"key":"6230_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s41669-019-0152-1","volume":"4","author":"N Boytsov","year":"2020","unstructured":"Boytsov N, Zhang X, Evans KA et al (2020) Impact of plan-level access restrictions on effectiveness of biologics among patients with rheumatoid or psoriatic arthritis. PharmacoEcon-Open 4:105\u2013117","journal-title":"PharmacoEcon-Open"},{"key":"6230_CR39","first-page":"104","volume":"27","author":"MA Youssef","year":"2021","unstructured":"Youssef MA, El Rafey DS (2021) Impact of biologics drugs adherence on treatment outcomes and work productivity of Al Sharqia Governorate patients with ankylosing spondylitis. Zagazig Univ Med J 27:104\u2013114","journal-title":"Zagazig Univ Med J"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06230-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06230-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06230-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T19:59:13Z","timestamp":1700683153000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06230-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,7]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["6230"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06230-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,7]]},"assertion":[{"value":"6 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Researchers accessed data in the format of a limited dataset for which data use agreements were in place with the covered entities in compliance with the Health Insurance Portability and Accountability (HIPAA) Privacy Rule. All data analyses and results occurred in a de-identified and aggregated format. During the course of secondary use of data in observational research, information pertaining to adverse events was not discovered because the study did not involve identifiable patient data associated with a Lilly product.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JRC reported financial relationships with AbbVie, Amgen, BMS, Corrona, Eli Lilly and Company, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB. KI is an Anthem employee and shareholder. MG and CCT are employees of HealthCore, Inc., which was under contract with Eli Lilly and Company for conducting the study on which this manuscript is based. MG is an Anthem shareholder. TH, JB, KG, MS, JW and JL are employees and shareholders of Eli Lilly and Company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}